The genetic polymorphism of thiopurine methyltransferase (TPMT) is one of the most developed examples of pharmacogenetics, spanning from molecular genetics to clinical diagnostics for individualizing thiopurine therapy (i.e. azathioprine, mercaptopurine, and thioguanine). Elucidation of the molecular mechanisms and biochemical consequences of TPMT deficiency demonstrates how pharmacogenetic traits can be identified, characterized, and translated to the bedside. Insights gained from studies of the TPMT polymorphism illustrate the potential of pharmacogenomics to optimize cancer therapy by avoiding toxic side effects in genetically distinct subgroups of patients.
Introduction
Interest in thiopurine S-methyltransferase (TPMT) emerged initially because of the important role this enzyme plays in metabolic transformation of the widely used anticancer and anti-inflammatory drugs mercaptopurine, thioguanine, and azathioprine (Elion, 1989) . Introduction of thiopurines, along with other antileukemic agents, increased the survival rates of children with acute lymphoblastic leukemia (ALL), from less than 5% in the early 1940s to 80% today.
In the 1960s, studies on the metabolism of thiopurines led to discovery of a specific methylase able to transfer the methyl group from S-adenosyl methionine (SAM) to the sulfur atom of thiopurines ( Figure 1 ). Charles Remy was the first to describe specific thiopurine S-methyltransferase activity in several species (Remy, 1963 (Remy, , 1967 , and the partially purified protein was subsequently characterized by Woodson and Weinshilboum (1983) . The first inactive allele of TPMT in humans was identified in 1995 (Krynetski et al., 1995b) .
Thiopurine methyltransferase (TPMT) is a cytoplasmic transmethylase present in prokaryotes and eukaryotes. Originally found in the kidney and liver of rats and mice, it was subsequently shown to be present in most human tissues, for example, heart, blood cells, placenta, pancreas, and intestine. Human TPMT has a molecular mass of 28 kDa, comprises 245 amino acids, and is not metal-dependent. TPMT catalyses methylation of mercaptopurine, thioguanine, and thiopurine nucleotides and nucleosides (Deininger et al., 1994; Krynetski et al., 1995a) . TPMT chromosomal gene is 27 kB long Seki et al., 2000) ; it maps to chromosome 6p22.3 and encompasses 10 exons (Szumlanski et al., 1996; Krynetski et al., 1997) . There is a processed pseudogene on chromosome 18 in the human genome (Szumlanski et al., 1996) .
Clinical importance of the TPMT polymorphism
The genetic polymorphism of TPMT is one of the most developed examples of pharmacogenetics, spanning from molecular genetics to clinical diagnostics for individualizing thiopurine therapy, a group of widely prescribed drugs including azathioprine, mercaptopurine, and thioguanine McLeod et al., 2000) . These agents are commonly used to treat leukemia, rheumatic diseases, inflammatory bowel diseases, and in solid organ transplantation. In hematopoietic tissues, TPMT catalyses the predominant inactivation pathway of thiopurines; hence, patients who inherit TPMT deficiency accumulate excessive concentrations of the active thioguanine nucleotides, with standard doses of these medications. TPMT activity exhibits genetic polymorphism; approximately 90% of individuals inherit high activity, 10% intermediate activity due to heterozygosity, and 0.3% have low or no detectable enzyme activity because they inherit two nonfunctional TPMT alleles (Figure 1 ) (Otterness et al., 1997; Yates et al., 1997) .
Numerous studies have shown that TPMT-deficient patients are at high risk for severe, and sometimes fatal, hematological toxicity (Evans et al., 1991; McLeod et al., 1993; Schutz et al., 1993; Evans et al., 2001) , and patients who are TPMT heterozygotes have an intermediate risk of hematological toxicity (Black et al., 1998; Relling et al., 1999a) . Incidentally, there is no evidence of increased thiopurine hepatotoxicity in patients with decreased TPMT activity (Evans et al., 2001) . As depicted in Figure 2 , patients who inherit two mutant alleles should be treated with 6-10% of the standard dose of thiopurines, while heterozygous patients can usually start on full doses, but have a significantly higher probability of requiring a dose reduction to avoid toxicity. TPMT deficiency has also been associated with a higher risk of irradiation-induced brain tumors in patients treated with thiopurines concomitant with radiation therapy (Relling et al., 1999c) . The molecular basis for polymorphic TPMT activity has now been defined (see below), and TPMT genotyping is now available as a CLIA-certified molecular diagnostic from reference laboratories (e.g. http://www.prometheuslabs.com).
Activation of prodrugs and determinants of drug concentration
MP and TG are inactive prodrugs, requiring metabolism to thiopurine nucleotides to exert cytotoxicity, the first step being conversion to thiopurine nucleotides (thioinosine monophosphate or thioguanosine monophosphate, respectively), with this phosphoribosylation catalysed by hypoxanthine phosphoribosyltransferase (HPRT) (Figure 1 ). Cells lacking this enzyme are resistant to thiopurines, and clinical manifestations of HPRT deficiency are well known as the Lesch-Nyhan syndrome (Jinnah and Friedmann, 2000) . A partial decrease in HPRT activity is not necessarily linked to classic Lesch-Nyhan syndrome, suggesting that variations in thiopurine activation are possible due to polymorphisms in the HPRT gene (Srivastava et al., 2002) . While decreased HPRT activity is a wellcharacterized mechanism of thiopurine resistance in cultured cells, variations of HPRT activity in ALL cells did not account for clinical differences in thiopurine metabolism (Pieters et al., 1992) .
Similar to other cytotoxic drugs, resistance to thiopurines may be due to alterations in the intracellular transportation of active metabolites (Bemi et al., 1999) . Indeed, in vitro experiments demonstrated that multidrug-resistance proteins 4 and 5 (MRP4 and MRP5), members of the ATP-binding cassette superfamily of transmembrane proteins, are able to mediate the cellular exclusion of xenobiotics, and increase the efflux of thiopurine nucleotides (Wijnholds et al., 2000; Chen et al., 2001; Wielinga et al., 2002) . The increased efflux of thiopurine nucleotides was hypothesized as a mechanism for cell resistance to thiopurines, but the clinical importance of enhanced MRP4/5-mediated efflux of thiopurines remains to be determined.
Methylation of thiopurine bases catalysed by thiopurine S-methyltransferase leads to metabolic inactivation, evidently due to alteration of the tautomeric form of the nucleobase (Figure 1 ). Methylation catalysed by TPMT is evidently the most important inactivation pathway of thiopurines in hematopoietic tissues, as xanthine oxidase is essentially absent in this tissue, and TPMT activity is inversely related to the accumulation of cellular TGNs and hematopoietic toxicity (Lennard et al., 1987) . Mercaptopurine and thioguanine, their nucleosides and the principal nucleotide metabolites (i.e. thioinosine monophosphate and thioguanosine monophosphate) are all substrates for human TPMT, with similar kinetic parameters (Krynetski et al., 1995a) . The product of TPMT-catalysed methylation of thioinosine monophosphate, methylthioinosine monophosphate, is a strong inhibitor of de novo purine biosynthesis; therefore, methylation of mercaptopurine metabolites can contribute to the effects of thiopurines (Hill and Bennett Jr, 1969; Dervieux et al., 2001 ). An important finding by Weinshilboum and Sladek (1980) was the discovery of polymorphic TPMT activity in erythrocytes (and subsequently other tissues), which family studies established as an autosomal codominant trait. This finding was later substantiated by other studies, and linked to thiopurine toxicity and efficacy (Lennard et al., 1990; Evans et al., 1991; McLeod et al., 1994) .
Genetic polymorphism and alleles of TPMT
The initial finding of inherited differences in TPMT activity in humans has now been elucidated at the molecular level by the identification of inactivating mutations in the human TPMT gene (Krynetski et al., 1995b; Szumlanski et al., 1996; Tai et al., 1996; Otterness et al., 1997 Otterness et al., , 1998 Loennechen et al., 1998 ; Spire-Vayrone de la Mourneyre Figure 1 Simplified schematic of thiopurine metabolism within cells illustrates important steps in the metabolic activation of mercaptopurine and thioguanine Drug methylation in cancer therapy E Krynetski and WE Evans Figure 2 Genetic polymorphism of TPMT, and its role in determining the response to thiopurine medications (azathioprine, mercaptopurine, thioguanine). The left panels depict the predominant TPMT mutant alleles causing autosomal codominant inheritance of TPMT deficiency in humans. As depicted in the subsequent top three panels, when uniform (conventional) dosages of thiopurine medications are administered to all patients, TPMT-deficient patients accumulate markedly higher (10-fold) cellular concentrations of the active thioguanine nucleotides (TGN) and heterozygous patients accumulated about twofold higher TGN concentrations, translating into a significantly higher frequency of hematopoietic toxicity (far right panels). As depicted in the bottom three panels, when genotype-specific dosing of thiopurines is administered, comparable cellular TGN concentrations are achieved, and all the three TPMT phenotypes can be treated without acute toxicity. Reproduced with permission from Evans (Pharmacogenetics, 12, 1-3, 2002) Drug methylation in cancer therapy E Krynetski and WE Evans et al., 1998; Hon et al., 1999; Colombel et al., 2000) . The first identified variant allele TPMT*2 contains a 238G4C transversion, leading to the substitution of a rigid proline for a more flexible alanine residue (Ala80Pro). As a result, the tertiary structure of the TPMT protein is changed, leading to protein instability and decreased catalytic activity (Krynetski et al., 1995b) .
TPMT*3A mutant allele contains two nucleotide transition mutations (460G4A and 719A4G) in the open reading frame (ORF), leading to the amino-acid substitutions (Ala154Thr and Tyr240Cys) (Szumlanski et al., 1996; Tai et al., 1996) . This allele encodes the highly unstable protein, and is associated with decreased level of TPMT (Tai et al., , 1999 . The similar deteriorating effect on protein stability has a single 719A4G mutation in the ORF of TPMT*3C allele (Otterness et al., 1997; Loennechen et al., 1998) .
Currently, approximately 11 variant alleles have been associated with low TPMT enzymatic activity in humans. Similar to variant alleles of other polymorphic enzymes, these alleles contain single-nucleotide polymorphisms (SNPs) leading to amino-acid substitutions (TPMT*2, *3A, *3B, *3C, *3D, *5, *6, *7, *8), formation of a premature stop codon (TPMT*3D), or destruction of a splice site (TPMT*4). Based on studies in various world populations to date (McLeod et al., 2000) , TPMT*3C, *3A, and *2 are the predominant variant alleles, accounting for over 95% of inherited TPMT deficiency, with the other variant alleles having been observed in very few individuals (in some cases, in only a single person, suggesting that these rare variants could be a mutation and not a true polymorphism).
Analysis of the genomic DNA in 24 unrelated Japanese individuals revealed the presence of 30 SNPs (one SNP per 907 bp), with one SNP in the 870 promoter region, 26 SNPs in introns, and three SNPs in the 3 0 -untranslated region of the TPMT gene locus (Seki et al., 2000) (Table 1 ). The 'wild-type' allele is designated TPMT*1, and the allele with a T474C silent mutation that does not lead to any change in enzymatic activity is designated TPMT*1S. Also, an allele *1A with a single SNP in exon 1 (À178 C4T) was detected in an individual with high TPMT activity (Spire-Vayron et al., 1998).
Protein activity and stability of mutant forms of TPMT
Experiments with heterologous expression of variant TPMT DNA in mammalian and yeast cells demonstrated that affinity of some of the variant TPMT proteins to substrate and SAM was sharply decreased (Tai et al., 1996) . Interestingly, while the transcription/ translation rate of variant TPMT proteins was comparable to that of wild-type TPMT, the stability of variant forms was significantly lower. Consequences of aminoacid substitutions in alleles *2, *3A, 3*B, and *3C have been extensively characterized in both in vitro and in vivo experiments, revealing enhanced proteolysis of the variant proteins (Tai et al., , 1999 .
Two major proteolytic pathways are responsible for the degradation of proteins in eukaryotic cells: an ATPdependent proteasomal pathway and an ATP-independent lysosomal pathway (Olson and Dice, 1989) . A proteasome-mutant yeast strain (pre-1) was utilized to further characterize the degradation of variant TPMT proteins . Both TPMT*2 and TPMT*3A were degraded more rapidly than wild-type TPMT in proteasome-competent strains, but both were slowly degraded in the pre-1 strain that lacked proteasomal degradation machinery. In contrast, there was no significant difference in degradation kinetics when cells were incubated in the presence or absence of chloroquine, at concentrations shown to inhibit lysosomal metabolism in yeast.
Surprisingly, TPMT*3C protein does not undergo enhanced proteolysis when expressed in yeast; yet, humans inheriting this allele have low TPMT activity and low protein levels. To address this apparent discrepancy, the proteolysis of wild-type and mutant TPMT was characterized in mammalian cells (COS-1). When expressed in COS-1 cells, all four mutant TPMT proteins, including TPMT*3C, had substantially lower steady-state levels and significantly (Seki et al., 2000) . b Nucleotide positions are counted from the first intronic nucleotide at the exon/intron junction (for SNP in the promoter region or in exon 9, the numbers indicate nucleotide positions with respect to the translation initiation site)
Drug methylation in cancer therapy E Krynetski and WE Evans shorter degradation half-lives when compared to the wild-type protein (Tai et al., 1999) . These findings of enhanced proteolysis of TPMT*2, *3A, and *3C proteins in mammalian cells are consistent with low or undetectable TPMT protein levels in cells of patients who inherited these variant alleles, and exemplify a potential limitation of yeast as a model for assessing proteolysis.
Variations of transcription
Another reason for the variability of TPMT activity is polymorphisms in the TPMT promoter. Deletion analysis of the TPMT promoter revealed that the basal level of TPMT mRNA is regulated by a DNA region located at (À116) to (À36) upstream from the transcription start site (Fessing et al., 1998b) . Interestingly, this region has a complex structure, and encompasses a variable number of tandem repeats that are highly homologous (Fessing et al., 1998b; Spire-Vayron et al., 1999) . This polymorphic locus within the promoter region of TPMT was observed in a study of 54 unrelated European individuals (Spire-Vayron et al., 1999) . Five alleles containing four to eight tandem repeats in the promoter region were identified, each consisting of 17 or 18 bp units that contain putative binding sites for transcription factors. The most common alleles contain four or five repeats, occurring with frequencies of 55 and 34%, respectively. Transient transfection experiments demonstrated only a modest modulatory effect of VNTR alleles on promoter activity (Spire-Vayron et al., 1999) , though the clinical importance of these findings still remains to be elucidated (Spire-Vayron et al., 1999; Yan et al., 2000; Alves et al., 2001 ).
Variation of TPMT activity and cellular resistance
Currently, two mechanisms are considered to contribute to the cytotoxic effects of thiopurines: incorporation of deoxythioguanosine into DNA and inhibition of de novo purine synthesis (DNPS) by methylated TIMP. Experiments with cells transfected with TPMT cDNA demonstrated that both processes are affected by increased TPMT activity. A retroviral gene transfer technique was used to develop human lymphoblastoid cell lines overexpressing TPMT (Dervieux et al., 2001) . These experiments unambiguously demonstrated that the activity of TPMT modulates the level of intracellular thiopurine metabolites. Transgenic cells with high levels of TPMT activity had 9-10-fold higher cytosolic concentrations of methylated thionucleotides (methylthioguanosine nucleotides or methylthioinosine nucleotides), compared with mock-transfected cells. Correspondingly, the intracellular concentration of nonmethylated thionucleotides was lower. Decrease in nonmethylated metabolites was associated with a decrease of thioguanosine incorporation into DNA. This finding supports the clinical observation of 95 pediatric patients treated with mercaptopurine, where the subgroup with lower concentrations of thioguanosine nucleotides in RBC (below the population median) had significantly higher TPMT activity and a higher rate of leukemic relapse, compared to those having TGN above the population median (Lennard et al., 1990) .
Interestingly, when treated with mercaptopurine, the cells with high TPMT activity had a significant decrease in DNPS, evidently due to greater formation of methylated TIMP, a known inhibitor of phosphoribosylpyrophosphate amidotransferase (PRP-AT), the enzyme catalyzing the first step in DNPS. Thus, DNPS inhibition is an additional mechanism of cytotoxicity with mercaptopurine. In contrast, methylated metabolites of thioguanine are weaker inhibitors of PRP-AT and, correspondingly, of DNPS (Allan and Bennett Jr, 1971). These results are consistent with clinical observations: methylthioinosine monophosphate is probably the most abundant metabolite after mercaptopurine administration in individuals with wild-type TPMT activity (Relling et al., 1999b) . Although TPMT-deficient patients must be treated with markedly lower doses of mercaptopurine to avoid toxic concentrations of TGN, these patients do not form methylated thionucleotides and thus tolerate higher TGN concentrations (Lennard et al., 1987 (Lennard et al., , 1990 Relling et al., 1999b) . Thus, mercaptopurine has two potential mechanisms of cytotoxicity (incorporation of thionucleosides into DNA and inhibition of DNPS by methylated metabolites), and TPMT plays an important role in both.
Evolutionary conservation and biological role of TPMT
TPMT has been intensively studied during the last 20 years, because of the importance of this enzyme for thiopurine chemotherapy. Nevertheless, many important questions still remain unanswered, particularly its biological role. Phenotypically, TPMT-deficient individuals appear to be indistinguishable from TPMTproficient persons, unless challenged with thiopurines. Considering that TPMT deficiency is a newly recognized and rare polymorphism, it is easy to assume that certain idiosyncrasies might be associated with it. One potentially useful approach for elucidating the biological function of this enzyme is comparative genomics.
The ancient origin of TPMT is evidenced by significant homology among TPMT sequences in distant species, such as primates, rodents, and bacteria. In particular, the structure of the murine TPMT chromosomal gene appears to be remarkably similar to that of the human gene. Sizes of all exons as well as positions of exon-intron boundaries coincided perfectly with those of the human gene . Like the human genome, the murine genome also contains a processed pseudogene, sharing 91% homology with the murine TPMT cDNA .
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Amino-acid sequence of murine TPMT also reveals significant similarity (82%, with 78% identical amino acids) to the human ortholog (Fessing et al., 1998a) . Moreover, the common inactivating mutations that result in the loss of TPMT activity in humans are located within the conserved regions of the polypeptide chain. For instance, SNPs that alter amino acids at positions 154 (460G4A) and 240 (719A4G) affect amino-acid residues that are invariant in TPMT from species as distant as Pseudomonas syringae and humans (Figure 3) .
Early reports of wide occurrence of TPMT activity in mammalian, avian, and amphibian species and several bacteria (Remy, 1963) were further supported by demonstration of TPMT activity in dogs, cats, and horses (Foster et al., 2000; White et al., 2000) . A bacterial gene encoding a protein with high homology to human TPMT was isolated from P. syringae, in line with early reports by Remy who detected TPMT activity in P. aeruginosa, fluorescens, and ovalis. This bacterial enzyme has TPMT activity, and was found to provide resistance to the bactericidal agent tellurite (Cournoyer et al., 1998) . More recently, heterologous expression of this gene in E. coli demonstrated that bacterial TPMT (bTPMT) catalyses methylation of selenite and methylselenocysteine to dimethylselenide and dimethyldiselenide (Ranjard et al., 2002) . Interestingly, human TPMT is also able to catalyse methylation of selenium-containing aromatic compounds (Deininger et al., 1994) .
Alignment of the amino-acid sequences in three distant taxa (primates, rodents, and bacteria) helped to identify signature sequences that presumably form catalytic/binding centers, or maintain the overall protein structure. Sequences homologous to TPMT have been detected in genomes of Ciona intestinalis, Halocynthia roretzi, and Oryzias latipes by computer search across genomic databases of available species (EK, unpublished) . Comparison of the bTPMT nucleotide sequence Figure 3 Amino-acid sequence comparison of TPMT family in human, rodents, and bacteria. Origin of sequences: human (TPMT2), P. putida (PPUTIDPRS_299), rat (RAT2), P. syringae (PSYRING_3817), P. syringae p.v. (PSYRING), P. putida (PPUTIDA_10788), P. aeruginosa (PAGP_287), mouse (MOUSE3), L. pneumophila (LPNEUMO_133), B. pseudomallei (BPSMALLE_840), B. pertussis (BPERTUSS_793), B. parapertussis (BPARAPER_1124), and V. cholerae (AE003852). Amino-acid residues affected by 460G4A and 719A4G SNPs in human TPMT*3A,B,and C alleles are marked by arrows. Alignment is prepared with AlignX software (Vector NTI package by InforMax, Bethesda, MD, USA) Drug methylation in cancer therapy E Krynetski and WE Evans across the microbial genome database demonstrated the existence of a conserved family of methyltransferases (Figure 4) . Genes encoding proteins highly homologous to TPMT have been detected in genomes of Vibrio cholerae, Legionella pneumophila, P. aeruginosa, P. putida, P. fluorescens, Bordetella pertussis, Bordetella parapertussis, Bordetella bronchoseptica, and several others (Figure 3) , though the corresponding biochemical or biological activities still remain to be elucidated. Interestingly, TPMT-like genes found in P. aeruginosa and V. cholerae belong to the same cluster of orthologous groups (COG) that contains SAM-dependent methyltransferases and tellurite-resistance determinants, including tehB from E. coli (Tatusov et al., 2001) . Tellurite resistance gene tehB of E. coli utilizes a methyltransferase activity in detoxification of tellurite (Liu et al., 2000) . Integration of these data suggests that the biological role of TPMT is probably methylation of sulfur-, selenium-, or tellurium-containing organic and inorganic compounds, with SAM being a source of the methyl group. Formation of dimethyl selenide constitutes a detoxification pathway in rats; therefore, a hypothetical role for human TPMT is detoxification of sulfur, selenium, or tellurium via conversion to relatively nontoxic methylation products (Hassoun et al., 1995) .
Determination of TPMT activity and genotype in humans
Introduction of a radiochemical assay (Weinshilboum et al., 1978) made it possible to carry out large-scale screening of TPMT activity in various populations, and, with some enhancements, is the method currently most widely used for monitoring TPMT activity in clinical studies. In this assay, erythrocytes are used as surrogate cells for drug-metabolizing tissues, and a strong correlation between TPMT activity in erythrocytes and other tissues, including leukemia cells, has been established (Van Loon and Weinshilboum, 1982; Woodson et al., 1982; Szumlanski et al., 1992; McLeod et al., 1995) .
Prospective identification of patients with decreased TPMT activity has evolved as a strategy to avoid thiopurine toxicity, while maintaining a therapeutic level of active metabolites. It should be noted that in patients who have received an RBC transfusion within 30-60 days, the TPMT activity in erythrocytes can be spuriously altered if a deficient or heterozygous patient is transfused with blood from a homozygous wild-type person. This is illustrated by one of the TPMT-deficient patients at our hospital (genotype TPMT*3A/*3A), who had an activity of 9.8 U/mL pRBC 12 days after receiving 2 U of packed erythrocytes, compared to undetectable activity 4 months after the heterologous erythrocyte transfusion. Since it is not uncommon for newly diagnosed leukemia patients or organ transplant recipients to receive allogeneic erythrocyte transfusions, molecular genetic methods that are not affected by donor erythrocytes have been developed, providing a more robust method to diagnose patients with TPMT deficiency or heterozygosity at the TPMT gene locus.
Several methods have been developed for determining TPMT genotype, which involve amplification of genomic DNA by PCR, or RT-PCR around the functionally important SNPs. Detection of individual SNPs is then achieved by a variety of methods, including RFLP, allele-specific amplification, direct sequencing, SSCP or DHPLC analysis ; Spire-Vayrone de la Mourneyre et al., 1998; Alves et al., 1999; Seki et al., 2000; Schaeffeler et al., 2001) . DNA-based methods to prospectively diagnose TPMT deficiency offer a clinically important strategy to minimize the risk of potentially life-threatening hematopoietic toxicity in patients treated with these medications (Black et al., 1998; Relling et al., 1999b; Scerri, 1999; Coulthard et al., 2000) . Genotyping for the three most common TPMT SNPs (238G4C, 460A4G, 719G4A) represents a molecular diagnostic with more than 95% concordance between TPMT genotype and phenotype. This level of concordance has been achieved in different populations at multiple institutions Coulthard et al., 1998; Rossi et al., 2001) , demonstrating the Figure 4 Phylogenetic tree of TPMT protein sequences in mammals and bacteria Drug methylation in cancer therapy E Krynetski and WE Evans feasibility of genotyping techniques in detecting genetic polymorphisms, although it is recognized that other rare SNPs exist and additional mechanisms of variable TPMT activity remain to be elucidated (Ando et al., 2001; Rossi et al., 2001 ).
Molecular haplotyping of TPMT alleles and population studies
While detection of individual SNPs within the TPMT ORF is a well-established and robust procedure, certain combinations of alleles present a source of potential ambiguity with conventional genotyping methods. As indicated earlier, the most common nonfunctional variant allele of TPMT in Caucasians is TPMT*3A, with the frequency of the heterozygous genotype *1/*3A found in about 10% of Caucasians. Individuals with this genotype have one active TPMT allele, and their risk of thiopurine hematopoietic toxicity is greater than patients who have a homozygous wild-type TPMT genotype (B35 vs B7%), but not as great a risk as those who have two nonfunctional TPMT alleles (B100%) (Relling et al., 1999a) .
On the other hand, individuals with the *3B/*3C genotype, who are compound heterozygotes, are phenotypically TPMT-deficient, and are at a very high risk of thiopurine toxicity (Schutz et al., 2000) . Though the *3B allele is rare, this allele has been reported by several investigators; thus, the *3B/*3C genotype cannot be ruled out when individuals are heterozygous for both the 460G4A and 719A4G SNPs. Using the conventional PCR genotyping analysis, it is not possible to distinguish between the *1/*3A and *3B/*3C genotypes, posing a potential diagnostic problem because thiopurine dosing is markedly different in these two genotypes (Brouwer et al., 2001) .
To resolve the ambiguity of conventional genotyping methods, a molecular haplotyping method using genomic DNA was developed, which permits haplotype determination for multiple SNPs located kilobases apart (McDonald et al., 2002) . This method uses long-range PCR to amplify regions of genomic DNA that include distantly spaced SNPs of interest at the opposite ends of the generated fragments, then intramolecular ligation (circularization) to bring these SNPs into close physical proximity, followed by the use of PCR-RFLP, allelespecific amplification (ASA), or allele-specific oligonucleotide ligation (ASO) analysis to determine whether the SNPs reside on the same or different alleles ( Figure 5 ). Using this new haplotype-specific method of detecting TPMT SNPs, it is straightforward to discriminate the TPMT*1/*3A genotype from the *3B/ *3C genotype using genomic DNA, without cloning, physical separation of chromosomes or sophisticated instrumentation.
Population studies in Caucasian, East and West African, African American, Chinese, Japanese and Southwest Asian populations have established significant racial or ethnic differences in the distribution of variant TPMT alleles (McLeod et al., 2000; Weinshilboum, 2001 ). For example, Southwest Asians (Indian, Pakistani) have a lower frequency of variant TPMT alleles, and all variant alleles identified to date are TPMT*3A. In contrast, East and West African populations appear to have a frequency of variant alleles similar to that of Caucasians, but all variant alleles in the African population are TPMT*3C. Furthermore, TPMT*3C accounts for approximately 50% of variant TPMT alleles in African Americans, but TPMT*3C comprises only about 5% of variant alleles in US Caucasians. Studies in a Japanese population revealed only TPMT*3C allele (Ishioka et al., 1999; Ando et al., 2001; Kubota and Chiba, 2001; Kumagai et al., 2001) . In northern Norway, the most predominant allele in Saamis was TPMT*3C, representing 92% of the variant alleles, while the most frequent variant allele in Caucasians living in the same geographic area was TPMT*3A, representing 91% of the variant alleles (Loennechen et al., 2001) . TPMT*3A accounts for more than 80% of variant alleles in white populations in the US and Northern Europe, but for only approximately 17% of variant alleles in African Americans.
In parallel, there are significant differences in the distribution of TPMT activity among different populations: while a trimodal distribution consistent with autosomal co-dominant inheritance is observed in Caucasian populations, a unimodal pattern of high TPMT activity has been reported for Korean (Jang et al., 1996; Park-Hah et al., 1996) and Jewish populations (Lowenthal et al., 2001) . The molecular basis for these population differences has not been fully elucidated.
Anthropologically, these findings indicate that 719A4G was the first TPMT SNP to arise in humans, because this is the only mutation found in both Chinese and African populations, and is found in Caucasians, either alone in TPMT*3C or in combination with 460G4A in TPMT*3A. Thus, the ancestral TPMT*3C allele probably acquired the 460G4A mutation after the divergence of the African and non-African populations about 100 000 years ago (Ingman et al., 2000) . A clinically important consequence of this finding is that the same molecular methods can be used to diagnose TPMT deficiency and heterozygosity in all world populations studied to date, because the predominant SNPs (238G4C, 460G4A, 719A4G) are the same. Pending questions and future perspective Despite significant progress in the study of this important enzyme, several questions still remain to be answered. Elucidation of the spatial structure of TPMT may shed light on the mechanism of its action, as well as provide a rational strategy to develop specific inhibitors of TPMT. Such inhibitors may be useful in improving thiopurine-based therapeutic protocols, if they can reduce interpatient variability in thiopurine absorption and disposition. To further investigate the phenotypic consequences of TPMT deficiency, the murine TPMT gene was isolated and characterized , opening the way to a mouse model in which the TPMT gene has been disrupted (i.e. TPMT-KO). Finally, gene expression and regulation patterns in TPMT-deficient vs TPMT-proficient cells and mice using DNA arrays may reveal the functional roles this protein plays in homeostasis.
The number of clinically important applications of molecular genetics of TPMT is constantly increasing, from the initial screening of TPMT polymorphism in ALL patients to prevent toxicity, to the increasingly common use of TPMT phenotyping/genotyping in other patient populations where thiopurines are prescribed, including solid organ transplant recipients, patients with Crohn's disease, systemic lupus erythematosus, nonbullous inflammatory dermatoses, rheumatoid arthritis, and other autoimmune diseases. Based on the patient's TPMT genotype, more rational planning of thiopurine therapy has now become possible.
Insights gained from the studies of TPMT polymorphism offer a broad perspective of how pharmacogenomics can help to achieve therapeutic goals while avoiding toxic side effects in genetically distinct groups of patients. Elucidation of the molecular mechanisms and biochemical consequences of TPMT deficiency requires integration of diverse approaches from different fields of biomedical science.
TPMT deficiency is a monogenic trait that affects a single (to the best of our current knowledge) biochemical reaction important for therapy with a very narrow class of drugs. These features make TPMT deficiency a nice example of how the pharmacogenetic traits can be identified, elucidated at the biochemical and molecular genetic level, and translated to the bedside. However, with most medications, a single monogenic trait will not be sufficient to explain inherited differences in drug response; rather a network of genes will govern drug disposition and response (Evans and McLeod, 2002) . As these polygenic traits are elucidated, it will become possible to more accurately optimize drug therapy based on each patient's ability to metabolize, transport, and respond to medications.
